Home / Psoriasis / Association of psoriasis with comorbidity development in children with psoriasis

Association of psoriasis with comorbidity development in children with psoriasis

Tollefson MM, et al. – Researchers designed this study to ascertain the risk of elevated lipid levels (hyperlipidemia/hypertriglyceridemia), hypertension, metabolic syndrome, polycystic ovarian syndrome, diabetes, nonalcoholic liver disease, and elevated liver enzyme levels in children with and without psoriasis, after accounting for obesity. They identified a higher risk of developing comorbidity among children with psoriasis than children without psoriasis. For the development of the comorbidities, while psoriasis was a small independent risk factor, obesity was a much stronger contributor to comorbidity development in children with psoriasis.


  • Researchers performed this retrospective cohort study of claims data from Optum Laboratories Data Warehouse (includes 150 million privately insured and Medicare enrollees).
  • They identified a cohort of 29,957 children with psoriasis (affected children) and an age-, sex-, and race-matched comparator cohort of 29,957 children without psoriasis and divided these into 4 groups:
    • Nonobese, without psoriasis (reference cohort);
    • Nonobese, with psoriasis;
    • Obese, without psoriasis; and
    • Obese, with psoriasis.
Full Article

About Dr. J. Kim

Dr Kim developed (and is continuing to develop) dermatology research news as we way from dermatologists to stay on top of the latest advances in the field of dermatology.

Check Also

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-1)

Study Description Go to  Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis. Condition or disease Intervention/treatment Phase Psoriasis Drug: Mirikizumab Drug: Placebo Phase 3 …

Leave a Reply

Your email address will not be published. Required fields are marked *